FDA’s Gottlieb: Any FDA/CMS Collaboration Efforts Should Occur Postmarket
This article was originally published in The Gray Sheet
Executive Summary
FDA and CMS should streamline their internal review processes before pursuing collaborative efforts to avoid an overly burdensome review process, according to FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD